User profiles for Santabhanu Chakrabarti
Santabhanu ChakrabartiClinical Associate Professor, Department of Medicine , University of British Columbia Verified email at mail.ubc.ca Cited by 1257 |
Outcome of apparently unexplained cardiac arrest: results from investigation and follow-up of the prospective cardiac arrest survivors with preserved ejection fraction …
…, R Yee, R Leather, S Chakrabarti… - Circulation …, 2016 - Am Heart Assoc
Background— The Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER)
enrolls patients with apparently unexplained cardiac arrest and no evident cardiac …
enrolls patients with apparently unexplained cardiac arrest and no evident cardiac …
Balloon expandable stent implantation for native and recurrent coarctation of the aorta—prospective computed tomography assessment of stent integrity, aneurysm …
S Chakrabarti, D Kenny, G Morgan, SL Curtis… - Heart, 2010 - heart.bmj.com
Background Stenting for aortic coarctation is known to be effective in the medium term.
Aneurysm formation following stent implantation is a recognised complication. However, data …
Aneurysm formation following stent implantation is a recognised complication. However, data …
Efficacy and safety of same-day discharge for atrial fibrillation ablation
…, P Khairy, R Zhang, L Ding, S Chakrabarti… - Clinical …, 2020 - jacc.org
Objectives The purpose of this study was to evaluate the efficacy, health care utilization, and
safety of a same-day discharge protocol. Background Catheter ablation of atrial fibrillation (…
safety of a same-day discharge protocol. Background Catheter ablation of atrial fibrillation (…
[HTML][HTML] Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide …
…, T Moe, M Lipczyńska, SF Tsai, S Chakrabarti… - International journal of …, 2020 - Elsevier
Background Current guidelines consider vitamin K antagonists (VKA) the oral anticoagulant
agents of choice in adults with atrial arrhythmias (AA) and moderate or complex forms of …
agents of choice in adults with atrial arrhythmias (AA) and moderate or complex forms of …
[HTML][HTML] Bystanders are less willing to resuscitate out-of-hospital cardiac arrest victims during the COVID-19 pandemic
…, D Guh, KN Dainty, J Helmer, S Saini, A Chakrabarti… - Resuscitation …, 2020 - Elsevier
Aim The COVID-19 pandemic may influence the willingness of bystanders to engage in
resuscitation for out-of-hospital cardiac arrest. We sought to determine if and how the pandemic …
resuscitation for out-of-hospital cardiac arrest. We sought to determine if and how the pandemic …
Comparison of ajmaline and procainamide provocation tests in the diagnosis of Brugada syndrome
…, M Gardner, JA Yeung-Lai-Wah, S Chakrabarti… - JACC: Clinical …, 2019 - jacc.org
Objectives : The authors studied the response rates and relative sensitivity of the most
common agents used in the sodium-channel blocker (SCB) challenge. Background : A type 1 …
common agents used in the sodium-channel blocker (SCB) challenge. Background : A type 1 …
Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER)
…, S Sanatani, P Angaran, RM Gow, S Chakrabarti… - Heart rhythm, 2014 - Elsevier
Background Provocative testing with sodium channel blockers is advocated for the evaluation
of unexplained cardiac arrest (UCA) with the primary purpose of unmasking the typical …
of unexplained cardiac arrest (UCA) with the primary purpose of unmasking the typical …
Evolution of clinical diagnosis in patients presenting with unexplained cardiac arrest or syncope due to polymorphic ventricular tachycardia
…, M Talajic, K Ahmad, B Gerull, S Chakrabarti… - Heart Rhythm, 2014 - Elsevier
Background A systematic evaluation of patients with unexplained cardiac arrest (UCA) yields
a diagnosis in 50% of the cases. However, evolution of clinical phenotype, identification of …
a diagnosis in 50% of the cases. However, evolution of clinical phenotype, identification of …
Cardiac sarcoidosis
…, ACT Ha, LJ Gula, S Chakrabarti… - Clinics in chest …, 2015 - chestmed.theclinics.com
Studies have suggested that clinically manifest cardiac involvement occurs in perhaps 5%
of patients with pulmonary/systemic sarcoidosis. Clinical features of CS depend on the …
of patients with pulmonary/systemic sarcoidosis. Clinical features of CS depend on the …
[HTML][HTML] Treatment and prevention of cardiovascular implantable electronic device (CIED) infections
An expanded role for cardiac implantable electronic devices (CIEDs) in recent decades
reflects an aging population and broader indications for devices, including both primary …
reflects an aging population and broader indications for devices, including both primary …